Literature DB >> 7636912

Maintenance of serum albumin levels in pediatric burn patients: a prospective, randomized trial.

D G Greenhalgh1, T A Housinger, R J Kagan, M Rieman, L James, S Novak, L Farmer, G D Warden.   

Abstract

A prospective, randomized trial was performed to determine whether maintaining serum albumin levels in burned pediatric patients had any effect on morbidity and mortality. Patients < 19 years of age with burns > 20% total body surface area were randomized to receive supplemental albumin to maintain levels 2.5 to 3.5 g/dL ("High Albumin") or were given albumin only if levels dropped < 1.5 g/dL ("Low Albumin") after completing burn shock resuscitation. The 36 patients in the Low Albumin group were well matched for age, burn size, depth of injury, and inhalation injury when compared with the High Albumin group (34 patients). As expected, serum albumin levels were significantly lower in the Low Albumin group when compared with the High Albumin group. No differences between groups were noted for resuscitation needs, maintenance fluid requirements, urine output, tube feedings received, days of antibiotic treatment, or ventilatory requirements. No differences in hematology, electrolytes, or nutritional laboratories were found. Finally, length of stay, complication rate, and mortality were not affected by albumin treatment. Albumin supplementation to maintain normal serum levels does not seem to be warranted in previously healthy children who suffer severe burns and who receive adequate nutrition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636912     DOI: 10.1097/00005373-199507000-00009

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  13 in total

Review 1.  Human albumin solution for resuscitation and volume expansion in critically ill patients.

Authors:  Ian Roberts; Karen Blackhall; Phil Alderson; Frances Bunn; Gillian Schierhout
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Fluid resuscitation in neonatal and pediatric hypovolemic shock: a Dutch Pediatric Society evidence-based clinical practice guideline.

Authors:  Nicole Boluyt; Casper W Bollen; Albert P Bos; Joke H Kok; Martin Offringa
Journal:  Intensive Care Med       Date:  2006-05-24       Impact factor: 17.440

Review 3.  Intravenous Fluid Therapy in Traumatic Brain Injury and Decompressive Craniectomy.

Authors:  Hernando Raphael Alvis-Miranda; Sandra Milena Castellar-Leones; Luis Rafael Moscote-Salazar
Journal:  Bull Emerg Trauma       Date:  2014-01

4.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

5.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 6.  [Guidelines on therapy with blood components and plasma derivatives: human albumin. Recommendations of the scientific advisory board of the Medical Council].

Authors:  J Boldt
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

Review 7.  Choosing a volume expander in critical care medicine.

Authors:  Niranjan Kissoon; Desmond Bohn
Journal:  Indian J Pediatr       Date:  2003-12       Impact factor: 1.967

Review 8.  Overview of Albumin Physiology and its Role in Pediatric Diseases.

Authors:  Charles B Chen; Bilasan Hammo; Jessica Barry; Kadakkal Radhakrishnan
Journal:  Curr Gastroenterol Rep       Date:  2021-07-02

9.  Human albumin administration in critically ill patients: systematic review of randomised controlled trials.

Authors: 
Journal:  BMJ       Date:  1998-07-25

10.  Serum albumin level as a risk factor for mortality in burn patients.

Authors:  Olivia Alejandra Aguayo-Becerra; Carlos Torres-Garibay; Michel Dassaejv Macías-Amezcua; Clotilde Fuentes-Orozco; Mariana de Guadalupe Chávez-Tostado; Elizabeth Andalón-Dueñas; Arturo Espinosa Partida; Andrea Del Socorro Alvarez-Villaseñor; Ana Olivia Cortés-Flores; Alejandro González-Ojeda
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.